Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy

Radiology

Volumn 260, Issue 1, 2011, Pages 68-78

  Li, Sonia P ^a   Makris, Andreas ^a   Beresford, Mark J ^a   Taylor, N Jane ^b   Ah See, Mei Lin W ^a   Stirling, J James ^b   D'Arcy, James A ^c   Collins, David J ^c   Kozarski, Robert ^d   Padhani, Anwar R ^b  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGE DISTRIBUTION; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; TUMOR VASCULARIZATION; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CONTRAST MEDIA; ENGLAND; FEMALE; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959544192     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.11102493     Document Type: Article

References (27)

1. Cleator SJ, Makris A, Ashley SE, Lal R, Powles TJ. Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Ann Oncol 2005;16(2):267-272. (Pubitemid 40309308)
2. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16(8):2672-2685. (Pubitemid 28363030)
3. Padhani AR, Khan AA. Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy. Target Oncol 2010;5(1):39-52.
4. Ah-See ML, Makris A, Taylor NJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2008;14(20):6580-6589.
5. Boné B, Szabó BK, Perbeck LG, Veress B, Aspelin P. Can contrast-enhanced MR imaging predict survival in breast cancer? Acta Radiol 2003;44(4):373-378.
6. Pickles MD, Manton DJ, Lowry M, Turnbull LW. Prognostic value of pre-treatment DCEMRI parameters in predicting disease free and overall survival for breast cancer patients undergoing neoadjuvant chemotherapy. Eur J Radiol 2009;71(3):498-505.
7. Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001;19(4):1195-1206. (Pubitemid 32176298)
8. Parker GJ, Suckling J, Tanner SF, et al. Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. J Magn Reson Imaging 1997;7(3):564-574. (Pubitemid 28360876)
9. d'Arcy JA, Collins DJ, Padhani AR, Walker-Samuel S, Suckling J, Leach MO. Magnetic Resonance Imaging Workbench: analysis and visualization of dynamic contrast-enhanced MR imaging data. RadioGraphics 2006;26(2):621-632.
10. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997;7(1):91-101. (Pubitemid 28365643)
11. Fritz-Hansen T, Rostrup E, Larsson HBW, Søndergaard L, Ring P, Henriksen O. Measurement of the arterial concentration of Gd-DTPA using MRI: a step toward quantitative perfusion imaging. Magn Reson Med 1996;36(2):225-231. (Pubitemid 26271742)
12. Walker-Samuel S, Leach MO, Collins DJ. Evaluation of response to treatment using DCE-MRI: the relationship between initial area under the gadolinium curve (IAUGC) and quantitative pharmacokinetic analysis. Phys Med Biol 2006;51(14):3593-3602. (Pubitemid 44026420)
13. Walker-Samuel S, Parker CC, Leach MO, Collins DJ. Reproducibility of reference tissue quantification of dynamic contrast-enhanced data: comparison with a fixed vascular input function. Phys Med Biol 2007;52(1):75-89. (Pubitemid 46646267)
14. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3(1):32-35.
15. Martincich L, Montemurro F, De Rosa G, et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 2004;83(1):67-76. (Pubitemid 38141894)
16. Sobin LH, Wittekind C, eds. TNM classification of malignant tumours (UICC). 6th ed. New York, NY: Wiley-Liss, 2002.
17. Chollet P, Amat S, Belembaogo E, et al. Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer? Br J Cancer 2003;89(7):1185-1191.
18. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992;22(3):207-219.
19. Haybittle JL, Blamey RW, Elston CW, et al. A prognostic index in primary breast cancer. Br J Cancer 1982;45(3):361-366. (Pubitemid 12122304)
20. Fisher ER, Anderson S, Tan-Chiu E, Fisher B, Eaton L, Wolmark N. Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer 2001;91(8 Suppl):1679-1687. (Pubitemid 32319246)
21. Flaherty KT, Rosen MA, Heitjan DF, et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 2008;7(4):496-501. (Pubitemid 351847022)
22. Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008;26(28):4572-4578.
23. Johansen R, Jensen LR, Rydland J, et al. Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI. J Magn Reson Imaging 2009;29(6):1300-1307.
24. Bottini A, Berruti A, Bersiga A, et al. Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. Br J Cancer 2001;85(8):1106-1112. (Pubitemid 33052307)
25. Jones RL, Salter J, A'Hern R, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009;116(1):53-68.
26. Lee J, Im YH, Lee SH, et al. Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer. Cancer Chemother Pharmacol 2008;61(4):569-577.
27. Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007;99(2):167-170.